TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›NAUT›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

Nautilus Biotechnology, Inc. (NAUT) financials

Income statement

Nautilus Biotechnology, Inc. (NAUT) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Net income-$15.6M-$50.3M-$57.9M-$63.7M-$70.8M-$59.0M
EPS (diluted)-$0.54-$0.60-$0.46-$0.51-$0.56-$0.47

Cash flow

Nautilus Biotechnology, Inc. (NAUT) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$14.0M-$39.2M-$45.8M-$51.7M-$59.1M-$50.7M
Capital expenditures$921K$2.27M$2.32M$2.44M$2.12M$1.28M
Free cash flow-$14.9M-$41.5M-$48.1M-$54.2M-$61.3M-$52.0M

Balance sheet

Nautilus Biotechnology, Inc. (NAUT) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$36.6M$186M$115M$19.4M$27.6M$12.4M
Total assets$85.0M$398M$350M$306M$243M$191M
Total liabilities$6.31M$34.9M$35.1M$40.2M$34.0M$34.1M
Shareholders' equity-$29.7M$364M$315M$265M$209M$157M
Retained earnings-$30.3M-$80.6M-$139M-$202M-$273M-$332M
Shares (wtd avg diluted)29.1M84.5M125M125M125M126M

Every figure is extracted from Nautilus Biotechnology, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Nautilus Biotechnology, Inc.'s free cash flow?
-$52.0M in FY2025 (operating cash flow -$50.7M minus $1.28M of capital expenditures), from the SEC cash-flow statement.
Does NAUT pay a dividend?
Nautilus Biotechnology, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full NAUT analysis — verdict, score & filings →Is NAUT a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.